J&J And Boehringer Sign Diabetes Deals | June 28, 2010 Issue - Vol. 88 Issue 26 | Chemical & Engineering News
Volume 88 Issue 26 | p. 22 | Concentrates
Issue Date: June 28, 2010

J&J And Boehringer Sign Diabetes Deals

Department: Business
Keywords: diabetes, drug development, cancer

Johnson & Johnson’s Ortho-McNeil-Janssen Pharmaceuticals unit has signed diabetes drug development pacts with Diamyd Medical and Metabolex. Ortho will pay Diamyd $45 million up front for rights to develop the pharmaceutical protein rhGAD65, which is in Phase III trials as a treatment for newly diagnosed type 1 diabetes patients. Meanwhile, Ortho will pay Metabolex an undisclosed upfront payment as part of a development and license agreement involving compounds for the treatment of type 2 diabetes. Separately, Boehringer Ingelheim will pay Neurocrine Biosciences $10 million for rights to develop small molecules that activate GPR119, a G-protein-coupled receptor, as a way of treating type 2 diabetes.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment